NeuroSense Publishes Phase 2b PARADIGM Results In JAMA Neurology Showing PrimeC Slows ALS Progression, Reduces Complications, Modulates Disease Biomarkers

Benzinga Newsdesk www.benzinga.com Positive 68.6%

Neg 0% Neu 0% Pos 68.6%

Comments

No comments yet. Be the first!